Forum Topic News
  • Conversation: Sanofi set to acquire Kiadis for €308m

    • November 5, 2020 10:56 AM GMT
      • Post(s)

      Sanofi set to acquire Kiadis for €308m

      French pharma Sanofi is set to buy Kiadis for a total of €308 ($358m) for access to the biotech’s NK-cell technology platform and pipeline.
      Following the acquisition, Sanofi will be able to fully access Kiaidis’ off-the-shelf natural killer (NK) cell platform.
      This platform is based on NK-cells from a ‘unique universal donor’, which Kiadis says has the potential to make NK-cell therapy products available quickly and economically for a potentially wider range of indications.
      Part of Sanofi’s rationale for acquiring Kiaidis is to take control of this proprietary platform, while another focus will be on the NK-cell specialist’s pipeline products, which Sanofi hopes will complement its push into immuno-oncology.
      Sanofi licensed Kiadis’ pre-clinical K-NK004 programme for multiple myeloma in July, to use in combination with its CD38 inhibitor, Sarclisa.
      Other pipeline products include K-NK002, currently in phase 2 development for the prevention of post-transplant relapse in patients with acute myeloid leukaemia AML and myelodysplastic syndromes.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel